Angiotensin-converting-enzyme inhibitors (ACE inhibitors) and angiotensin II receptor blocker (ARB) use in COVID-19 prevention or treatment: A paradox

Infect Control Hosp Epidemiol. 2021 Jan;42(1):118-119. doi: 10.1017/ice.2020.195. Epub 2020 May 4.

Authors

Shaghayegh Haghjooy Javanmard¹, Kiyan Heshmat-Ghahdarijani², Golnaz Vaseghi³

Affiliations

¹ Applied Physiology Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran.
² Heart Failure Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran.
³ Isfahan Cardiovascular Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran.

No abstract available

Publication types

Letter

MeSH terms

Angiotensin Receptor Antagonists* / pharmacology
Angiotensin Receptor Antagonists* / therapeutic use
Angiotensin-Converting Enzyme 2 / metabolism
COVID-19* / prevention & control
COVID-19* / therapy
COVID-19* / virology
Cardiovascular Diseases / drug therapy
Cardiovascular Diseases / metabolism
Humans
Medication Therapy Management
SARS-CoV-2 / physiology*
Spike Glycoprotein, Coronavirus / metabolism
Virus Internalization / drug effects

Substances

Angiotensin Receptor Antagonists
Spike Glycoprotein, Coronavirus
Angiotensin-Converting Enzyme 2